Publicaciones en colaboración con investigadores/as de Columbia University Medical Center (19)

2022

  1. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis

    Leukemia, Vol. 36, Núm. 5, pp. 1432-1435

  2. Worldwide Disparities in Recovery of Cardiac Testing 1 Year Into COVID-19

    Journal of the American College of Cardiology, Vol. 79, Núm. 20, pp. 2001-2017

2021

  1. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer

    Genome Medicine, Vol. 13, Núm. 1

  2. Imetelstat achieves meaningful and durable transfusion independence in high transfusion–Burden patients with lower-risk myelodysplastic syndromes in a phase II study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 48-56

  3. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  4. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

2020

  1. Luspatercept in patients with lower-risk myelodysplastic syndromes

    New England Journal of Medicine, Vol. 382, Núm. 2, pp. 140-151

2019

  1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 229-240

  2. MFN2 mutations in charcot-marie-Tooth disease alter mitochondria-Associated er membrane function but do not impair bioenergetics

    Human Molecular Genetics, Vol. 28, Núm. 11, pp. 1782-1800

  3. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2016

  1. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

    American Journal of Hematology, Vol. 91, Núm. 6, pp. 575-580

  2. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients

    Leukemia and Lymphoma, Vol. 57, Núm. 9, pp. 2071-2076

  3. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. Designing a broad-spectrum integrative approach for cancer prevention and treatment

    Seminars in Cancer Biology, Vol. 35, pp. S276-S304

2014

  1. International Myeloma Working Group recommendations for global myeloma care

    Leukemia, Vol. 28, Núm. 5, pp. 981-992

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2011

  1. A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons

    Experimental Neurology, Vol. 229, Núm. 2, pp. 409-420